Department of Psychiatry and Psychotherapy III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany.
Department of Psychiatry and Psychotherapy III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany.
Psychiatry Res. 2018 Aug;266:323-327. doi: 10.1016/j.psychres.2018.03.031. Epub 2018 Mar 17.
Psychotropic drugs may induce impairments in the mouth, jaw and face area. Currently, appropriate pharmacoepidemiologic data are missing. Therefore, a questionnaire-based telephone survey of two non-representative samples of psychiatrists and dentists was conducted. Most of the psychiatrists (79.7%) and dentists (76.5%) indicated that psychotropic drugs may induce dental adverse drug reactions (ADR); in both samples there was an approximately equally sized, relevant proportion of participants who did not believe in the risk of dental ADR of psychotropic drugs (psychiatrists 20.3%; dentists 23.5%). About one third of the participants of both samples (psychiatrists 34.9%; dentists 35.9%) felt that dental ADRs of psychotropic drugs are a serious health problem. The majority of both groups (psychiatrists 97.8%; dentists 97.0%) had never reported a dental ADR. Most psychiatrists and dentists appeared to be aware of the risk of dental ADRs by psychotropic drugs. A relevant proportion of participants of both groups considered psychotropic drugs to be irrelevant regarding dental ADRs; therefore, there may be information needs in both groups. The willingness to report dental ADRs of psychotropic drugs was low in both groups; the evaluation of the actual relevance of this drug-related risk is impeded by the absence of reports of suspected ADRs.
精神药物可能会对口腔、颌面部造成损害。目前,缺乏适当的药物流行病学数据。因此,对两名非代表性的精神科医生和牙医样本进行了基于问卷的电话调查。大多数精神科医生(79.7%)和牙医(76.5%)表示,精神药物可能会引起药物不良反应;在这两个样本中,大约有同样比例的参与者不相信精神药物会导致口腔不良反应(精神科医生 20.3%;牙医 23.5%)。大约三分之一的两个样本参与者(精神科医生 34.9%;牙医 35.9%)认为精神药物引起的口腔不良反应是一个严重的健康问题。这两个群体的大多数人(精神科医生 97.8%;牙医 97.0%)从未报告过口腔不良反应。大多数精神科医生和牙医似乎意识到精神药物引起口腔不良反应的风险。两组的相当一部分参与者认为精神药物与口腔不良反应无关;因此,这两个群体都可能存在信息需求。两组报告精神药物口腔不良反应的意愿都较低;由于未报告疑似不良反应,实际评估这种药物相关风险的相关性受到阻碍。